Table 1.

Sample characteristics at baseline and 12 weeks

Characteristic	n (%)
Categorical variables	Baseline	12 weeks
Sex
Female	10 (56)	6 (50)
Male	8 (44)	6 (50)
Race
White	15 (83)	10 (83)
African-American	2 (11)	1 (8)
Hispanic	1 (6)	1 (8)
Relationship status
Never married	3 (17)	2 (17)
Married	7 (39)	5 (42)
Divorced/separated	2 (11)	1 (8)
Widowed	3 (17)	2 (17)
Living together	3 (17)	2 (17)
Household income
≤$24,999	3 (17)	2 (17)
$25,000-$49,999	2 (11)	1 (8)
$50,000-$99,999	5 (28)	4 (33)
$100,000-$149,000	1 (6)	1 (8)
Chose not to answer	7 (39)	4 (33)
Type of cancer
Breast	2 (11)	1 (8)
Colon	2 (11)	1 (8)
Lung	2 (11)	1 (8)
Bladder	1 (6)	1 (8)
Gynecologic (other than ovarian)	1 (6)	1 (8)
GI	1 (6)	0
Lymphoma	4 (22)	4 (33)
Ovarian	2 (11)	2 (17)
Other	3 (17)	1 (8)
Metastasis
Yes	5 (28)	1 (8)
No	13 (72)	11 (92)
Glycemic control based on A1c
<7.0	8 (47)	6 (50)
≥7.0	9 (53)	6 (50)
On insulin
Yes	5 (28)	3 (25)
No	13 (72)	9 (75)
Diabetes <5 years
Yes	5 (28)	4 (33)
No	13 (72)	8 (67)
Diabetes <10 years
Yes	9 (50)	6 (50)
No	9 (50)	6 (50)
Comorbidities
0-1	5 (28)	5 (42)
2-4	6 (33)	2 (16)
>5	7 (39)	5 (42)
Continuous variables	n	Mean (SD)
Age
Baseline	18	63 (11)
12 weeks	12	63 (12)
Years with diabetes
Baseline	18	10 (9)
12 weeks	12	8 (7)
Total number of other comorbidities
Baseline	18	3 (2)
12 weeks	12	3 (2)
Total symptom severity
Baseline	18	50 (25)
12 weeks	12	47 (32)
Total symptom interference
Baseline	18	39 (27)
12 weeks	12	33 (28)
Physical function
Baseline	18	30 (6)
12 weeks	12	31 (9)
Emotional function
Baseline	18	50 (10)
12 weeks	12	51 (10)
Cancer treatment impact on diabetes management
Baseline	Not measured	Not measured
12 weeks	12	32 (23)
Estimated daily average glucose (based on A1c)
Baseline	17	166 (33)
12 weeks	12	171 (39)

GI: Gastrointestinal, SD: Standard deviation